Business Description
ISIN : US31773D2009
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 94.37 | |||||
9-Day RSI | 76.45 | |||||
14-Day RSI | 66.46 | |||||
3-1 Month Momentum % | 36.24 | |||||
6-1 Month Momentum % | -23.4 | |||||
12-1 Month Momentum % | -20.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -16873.83 | |||||
OCF Margin % | -16873.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:FNCHQ
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Finch Therapeutics Group Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.107 | ||
| EPS (TTM) ($) | -8.82 | ||
| Beta | 1.13 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 3.85 | ||
| Volatility % | 54.97 | ||
| 14-Day RSI | 66.46 | ||
| 14-Day ATR ($) | 0.076746 | ||
| 20-Day SMA ($) | 10.22 | ||
| 12-1 Month Momentum % | -20.08 | ||
| 52-Week Range ($) | 2 - 16.1 | ||
| Shares Outstanding (Mil) | 1.61 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Finch Therapeutics Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Finch Therapeutics Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 65 days | ||
| Second quarter earnings results for 2026 | 2026-09-11 | In 2 days | ||
| Annual report for 2024 | 2025-04-23 | 12.75 (+0.00%) | ||
| 0.0333333:1 Stock Split | 2023-06-12 | 8.13 (+0.37%) |
Finch Therapeutics Group Inc Frequently Asked Questions
Guru Commentaries on OTCPK:FNCHQ
Finch Therapeutics decided to move forward with a strategic Chapter 11 bankruptcy filing to sell the company. The trial court ruling resulted in a disappointing judgement for damages of $25.8 million, with a royalty rate of 5.5%. The final sale value was $32 million, which was below expectations. Despite this, the investment was deemed worth making due to downside protection and the potential for a higher return. However, the time taken to get a court ruling was underestimated, leading to a disappointing outcome overall.
Finch Therapeutics is currently pursuing a strategic Chapter 11 filing to eliminate lease obligations and facilitate the sale of the company. This includes valuable assets such as a litigation claim against Ferring Pharmaceuticals, which could yield between $25 and $80 per share, and 160 issued patents. The company has received healthy interest from potential buyers, and the manager believes this process will maximize shareholder value more effectively than remaining publicly traded. A resolution is expected in early June, and the manager anticipates a healthy premium over the purchase price.
Finch Therapeutics has shown significant potential following a favorable jury trial outcome against Ferring Pharmaceuticals, which awarded Finch approximately $30 million and ongoing royalties. The jury's finding of willful infringement opens the door for enhanced damages, potentially tripling the award. The manager believes that even in a worst-case scenario, Finch shares are worth at least double their current price, indicating strong upside potential. The situation is deemed worth waiting for, reflecting confidence in Finch's future prospects.
Press Release
Articles on Finch Therapeutics Group Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
